ArticleNaunyn-Schmiedeberg's archives of pharmacology2020

Bufotalin ameliorates experimental Sjögren's syndrome development by inhibiting Th17 generation.

Yang Huang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.